目的评价Roux-en-Y胃空肠吻合术在远端胃大部切除消化道重建中的临床价值。 方法对笔者所在医院科室2009年1月至2012年7月期间31例远端胃癌行Roux-en-Y消化道重建患者的临床资料进行回顾性分析。 结果全组病例无围手术期死亡，无吻合口漏、十二指肠残端瘘、输入空肠段梗阻及倾倒综合征发生。28例（90.3%）患者术后半年进食3～4次/d，每餐量150～400 g；血红蛋白110～150 g/L，血清白蛋白38～50 g/L；24例（77.4%）患者体质量恢复或超过术前水平。胃镜检查未发现反流性食管炎，有残胃炎表现者3例，但无临床症状。 结论Roux-en-Y胃空肠吻合术可成为远端胃大部切除消化道重建的主要术式。
Objective To evaluate clinical efficacy of mFOLFOX6 combined with aspirin in treatment of advanced gastric cancer following perioperative period of laparoscopic distal subtotal gastrectomy. Methods One hundred and seven patients with advanced gastric cancer were assigned to observation group (57 cases) and control group (50 cases). The patients in the observation group received the mFOLFOX6 chemotherapy and regular intake of aspirin (100 mg/d) and the control group received the mFOLFOX6 chemotherapy alone. The recurrence or metastasis rate, rate of disease progress, toxicity, median survival time, and 3-year survival rate were compared between the observation group and the control group. Results ① There were no significant differences in the gender, age, pathological type, and so on between the observation group and the control group (P>0.05). ② The rates of toxicity such as the white blood cell reduction, granulocyte reduction, thrombocytopenia had no significant differences in these two groups (P>0.05). ③ The follow-up time was 4–45 months with an average 3.5 years, the rate of disease progress was lower (P=0.032), the median survival time was longer (P=0.043), the cumulative 3-year overall survival (P=0.015) and the cumulative 3-year disease-free survival (P=0.037) were better in the observation group as compared with the control group. Conclusion Preliminary results in this study show that mFOLFOX6 regimen combined with low-dose aspirin could significantly improve efficacy of advanced gastric cancer following perioperative period of laparoscopic distal subtotal gastrectomy, reduce rate of disease progress, and improve survival rate without increasing side effects.